Potent CDK9 inhibitor shows promise for overcoming drug resistance in hematological malignancies

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant mutant form, offering a promising strategy for treating hematological malignancies.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup